DK3814341T3 - Erbb-receptorinhibitorer - Google Patents

Erbb-receptorinhibitorer Download PDF

Info

Publication number
DK3814341T3
DK3814341T3 DK19800509.2T DK19800509T DK3814341T3 DK 3814341 T3 DK3814341 T3 DK 3814341T3 DK 19800509 T DK19800509 T DK 19800509T DK 3814341 T3 DK3814341 T3 DK 3814341T3
Authority
DK
Denmark
Prior art keywords
receptor inhibitors
erbb receptor
erbb
inhibitors
receptor
Prior art date
Application number
DK19800509.2T
Other languages
English (en)
Inventor
Zhengtao Li
Wei Zhong
Jiabing Wang
Qingbei Zeng
Honchung Tsui
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3814341T3 publication Critical patent/DK3814341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19800509.2T 2018-05-08 2019-05-08 Erbb-receptorinhibitorer DK3814341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018085998 2018-05-08
PCT/CN2019/085949 WO2019214634A1 (en) 2018-05-08 2019-05-08 Erbb receptor inhibitors

Publications (1)

Publication Number Publication Date
DK3814341T3 true DK3814341T3 (da) 2024-04-22

Family

ID=68467752

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19800509.2T DK3814341T3 (da) 2018-05-08 2019-05-08 Erbb-receptorinhibitorer

Country Status (15)

Country Link
US (2) US10822334B2 (da)
EP (2) EP3814341B1 (da)
JP (2) JP7540953B2 (da)
KR (1) KR102806778B1 (da)
CN (4) CN111747953B (da)
AR (1) AR117424A1 (da)
AU (1) AU2019267959B2 (da)
BR (1) BR112020022829A2 (da)
CA (1) CA3099315A1 (da)
DK (1) DK3814341T3 (da)
ES (1) ES2977196T3 (da)
MX (2) MX2020011868A (da)
PT (1) PT3814341T (da)
TW (2) TWI811358B (da)
WO (1) WO2019214634A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778589B1 (en) * 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
HRP20241743T1 (hr) * 2018-09-18 2025-02-28 F. Hoffmann - La Roche Ag Derivati kinazolina kao antitumorska sredstva
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
TWI879751B (zh) * 2020-03-23 2025-04-11 印度商皮埃企業有限公司 3-被取代的苯基脒化合物及其製備和用途
WO2022076304A1 (en) * 2020-10-05 2022-04-14 Dana-Farber Cancer Institute, Inc. Potent and selective inhibitors of her2
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024539212A (ja) * 2021-10-20 2024-10-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト キナゾリン誘導体の結晶形態、調製、組成物およびその使用
CN114262327B (zh) * 2021-12-30 2023-01-03 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
JP2025509995A (ja) * 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
EP4578457A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical for treating and/or preventing cancer
EP4637773A1 (en) 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Crystalline forms of a her2 inhibitor
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
IL326016A (en) 2023-07-28 2026-03-01 Boehringer Ingelheim Int Process for manufacturing a HER2 inhibitor
CN119320383A (zh) * 2023-09-05 2025-01-17 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
CN117658818B (zh) * 2023-11-03 2025-02-07 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
GB0504474D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
ES2364901T3 (es) * 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Also Published As

Publication number Publication date
EP4410291A3 (en) 2024-08-14
EP4410291A2 (en) 2024-08-07
CN112266384A (zh) 2021-01-26
BR112020022829A2 (pt) 2021-02-02
AR117424A1 (es) 2021-08-04
JP7810734B2 (ja) 2026-02-03
JP2024050653A (ja) 2024-04-10
ES2977196T3 (es) 2024-08-20
US10822334B2 (en) 2020-11-03
KR102806778B1 (ko) 2025-05-12
PT3814341T (pt) 2024-04-11
TW202344253A (zh) 2023-11-16
AU2019267959A1 (en) 2020-11-26
TWI858848B (zh) 2024-10-11
EP3814341A1 (en) 2021-05-05
CN111587248A (zh) 2020-08-25
CN111747953B (zh) 2021-05-07
JP7540953B2 (ja) 2024-08-27
CN111747953A (zh) 2020-10-09
TW202015690A (zh) 2020-05-01
US11447492B2 (en) 2022-09-20
JP2021523159A (ja) 2021-09-02
EP3814341B1 (en) 2024-03-20
TWI811358B (zh) 2023-08-11
CA3099315A1 (en) 2019-11-14
KR20210013071A (ko) 2021-02-03
EP3814341A4 (en) 2022-01-05
CN112266384B (zh) 2022-09-23
MX2020011868A (es) 2021-02-26
MX2023008954A (es) 2023-08-18
AU2019267959B2 (en) 2024-06-06
CN111662289A (zh) 2020-09-15
US20200317669A1 (en) 2020-10-08
WO2019214634A1 (en) 2019-11-14
US20210009587A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
DK3814341T3 (da) Erbb-receptorinhibitorer
IL283639A (en) Kif18a inhibitors
EP4007752C0 (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4069686C0 (en) GLP-1 RECEPTOR AGONIST
EP4007753C0 (en) Kif18a inhibitors
EP4007756C0 (en) KIF18A INHIBITORS
EP3746424A4 (en) ERBB / BTK INHIBITORS
EP3801503A4 (en) INHIBITORS OF SARM1
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA52813A (fr) Inhibiteurs de sarm1
EP3817736A4 (en) PIKFYVE INHIBITORS
MA52809A (fr) Inhibiteurs de sarm1
EP3804707A4 (en) KINASE INHIBITOR
EP3980011A4 (en) INHIBITORS OF SARM1
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP4076664C0 (en) Egfr inhibitors
EP3912517C0 (en) FRAME
EP3957391C0 (en) AGITATOR
EP4076665C0 (en) EGFR INHIBITORS
EP3976797A4 (en) ANTI-CRISPR INHIBITORS